Unibest
← Back to patent-cliff list

CAS 541-41-3

Carbonochloridic acid ethyl esterethyl carbonochloridateChloridocarbonic acid ethyl ester

Codes: (II)461018-4-a, EFAV-028, Tamsulosin Hydrochloride-088, SOLIF-002, SIME-015, IVAC-011, AZILS-006, S-pantoprazole sodium-057, LINE-012

Application context (from source-drug indications)

Waldenström macroglobulinaemiaIbrutinibChronic lymphocytic leukaemiaIbrutinibMantle cell lymphomaIbrutinibGraft-versus-host diseaseIbrutinibHIV infectionEfavirenz/Lamivudine/Tenofovir Disoproxil FumarateErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideHepatitis CSimeprevir SodiumChronic hepatitis CSimeprevir SodiumMeaslesSimeprevir SodiumMycobacterium tuberculosis infectionSimeprevir SodiumCystic fibrosisIvacaftorChronic bronchitisIvacaftorChronic obstructive pulmonary diseaseIvacaftorSinusitisIvacaftorHypertensionAzilsartanEssential hypertensionAzilsartanType 2 diabetesAzilsartanObesityAzilsartanDiabetesAzilsartanBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideGastro-oesophageal reflux diseaseS-pantoprazole sodiumPeptic ulcerS-pantoprazole sodiumHaemorrhageS-pantoprazole sodiumTrauma and injuryS-pantoprazole sodiumComaS-pantoprazole sodiumAspiration pneumoniaS-pantoprazole sodiumBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochlorideHIV infectionEfavirenzCreutzfeldt-Jakob diseaseEfavirenzAlzheimer's diseaseEfavirenzPancreatic cancerEfavirenzProstate cancerEfavirenzNon-Hodgkin lymphomaEfavirenzOveractive bladderSolifenacin SuccinateUrge incontinenceSolifenacin SuccinateUrinary tract diseaseSolifenacin Succinate非复杂性皮肤和皮肤结构感染LinezolidPneumoniaLinezolidComplicated skin and skin structure infectionLinezolidBacteraemiaLinezolidBacterial infectionLinezolidHealthcare-associated pneumoniaLinezolid

Source drugs (routes using this intermediate)

DrugTierExpiry
IbrutinibTier A — Act now2027
Efavirenz/Lamivudine/Tenofovir Disoproxil FumarateTier C — Watch / trade-
Tadalafil/TamsulosinTier C — Watch / trade-
Solifenacin Succinate/Tamsulosin HydrochlorideTier C — Watch / trade-
Simeprevir SodiumTier B — Position early-
IvacaftorTier B — Position early-
AzilsartanTier C — Watch / trade-
Dutasteride/Tamsulosin HydrochlorideTier C — Watch / trade-
S-pantoprazole sodiumTier C — Watch / trade-
Tamsulosin HydrochlorideTier C — Watch / trade-
EfavirenzTier B — Position early-
Solifenacin SuccinateTier B — Position early-
LinezolidTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.